533 related articles for article (PubMed ID: 21185724)
1. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
Singh MS; Francis PA; Michael M
Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
Gaston C; Kolesar J
Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis.
Seruga B; Amir E
Breast Cancer Res Treat; 2010 Aug; 122(3):609-17. PubMed ID: 20454926
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.
Briest S; Stearns V
Clin Adv Hematol Oncol; 2009 Mar; 7(3):185-92. PubMed ID: 19398943
[TBL] [Abstract][Full Text] [Related]
6. Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
Siegelmann-Danieli N; Kurnik D; Lomnicky Y; Vesterman-Landes J; Katzir I; Bialik M; Loebstein R
Breast Cancer Res Treat; 2011 Jan; 125(2):505-10. PubMed ID: 20593233
[TBL] [Abstract][Full Text] [Related]
7. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?
Brauch H; Jordan VC
Eur J Cancer; 2009 Sep; 45(13):2274-83. PubMed ID: 19592233
[TBL] [Abstract][Full Text] [Related]
8. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
[TBL] [Abstract][Full Text] [Related]
9. Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users.
Dieudonné AS; Lambrechts D; Claes B; Vandorpe T; Wildiers H; Timmerman D; Billen J; Leunen K; Amant F; Berteloot P; Smeets A; Paridaens R; Weltens C; Van Limbergen E; Van den Bogaert W; Vergote I; Van Huffel S; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 Dec; 118(3):531-8. PubMed ID: 19597703
[TBL] [Abstract][Full Text] [Related]
10. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.
Stingl JC; Parmar S; Huber-Wechselberger A; Kainz A; Renner W; Seeringer A; Brockmöller J; Langsenlehner U; Krippl P; Haschke-Becher E
Curr Med Res Opin; 2010 Nov; 26(11):2535-42. PubMed ID: 20849243
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
[TBL] [Abstract][Full Text] [Related]
12. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
Nowell SA; Ahn J; Rae JM; Scheys JO; Trovato A; Sweeney C; MacLeod SL; Kadlubar FF; Ambrosone CB
Breast Cancer Res Treat; 2005 Jun; 91(3):249-58. PubMed ID: 15952058
[TBL] [Abstract][Full Text] [Related]
13. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of endocrine therapy for breast cancer.
Higgins MJ; Stearns V
Annu Rev Med; 2011; 62():281-93. PubMed ID: 21226615
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomics of tamoxifen therapy.
Brauch H; Mürdter TE; Eichelbaum M; Schwab M
Clin Chem; 2009 Oct; 55(10):1770-82. PubMed ID: 19574470
[TBL] [Abstract][Full Text] [Related]
16. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
[TBL] [Abstract][Full Text] [Related]
17. Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?
Peppercorn J; A Carey L
Expert Rev Anticancer Ther; 2008 Feb; 8(2):191-4. PubMed ID: 18279059
[TBL] [Abstract][Full Text] [Related]
18. The ethics of CYP2D6 testing for patients considering tamoxifen.
Hartman AR; Helft P
Breast Cancer Res; 2007; 9(2):103. PubMed ID: 17433116
[TBL] [Abstract][Full Text] [Related]
19. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]